http://www.sciencedaily.com/releases...0323104949.htm
Quote:
|
In all, seven institutions from around the nation will be involved in the two-year study. The investigators plan to recruit 150 women who have not previously been treated for MS. They will be given either estriol along with Copaxone, an MS drug currently in use, or a placebo along with Copaxone. "That way, no one will receive less than the standard of care," Voskuhl said. The team will measure relapse rates over the course of the trial.
|
According to this, only women will be in the study, not men. Interesting.
http://www.ncbi.nlm.nih.gov/pubmed/14634144
Here's the clinical trial enrollment information:
http://www.clinicaltrials.gov/ct2/sh...rosis&rank=233